Adverse Events During Upper Gastrointestinal Endoscopy (AEDUGESSH)
Adverse Events During Upper Gastrointestinal Endoscopy With and Without Sedation: a Multiple Center Report From Shanghai
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Diansan Su, Doctor
- Phone Number: 0086-21-68383702
- Email: diansansu@yahoo.com
Study Contact Backup
- Name: Xiangrui Wang, Doctor
- Phone Number: 0086-21-68383198
- Email: wangxr2010@yahoo.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200065
- Recruiting
- Shanghai Tongji Hospital
-
Principal Investigator:
- Xiaoqing Zhang, M.S.
-
Shanghai, Shanghai, China, 200127
- Recruiting
- Renji Hospital, School of Medicine, Shanghai Jiaotong University
-
Contact:
- Diansan Su, Doctor
- Phone Number: 0086-21-68383702
- Email: diansansu@yahoo.com
-
Principal Investigator:
- Diansan Su, Doctor
-
Shanghai, Shanghai, China
- Recruiting
- Shanghai Pudong New Area People's Hospital
-
Contact:
- Lizhi Li, M.S.
- Email: Fmlilizhi@sina.com.cn
-
Principal Investigator:
- Lizhi Li, M.S.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients will undergo upper gastrointestinal endoscopy
- Age > 18 years old
- Signed informed consent form
Exclusion Criteria:
- Pregnant
- Allergy to propofol or soybean or albumen
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Sedation
patients underwent upper gastrointestinal endoscopy with sedation
|
|
non-sedation
patients underwent upper gastrointestinal endoscopy without sedation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Patients will be followed for the duration of hospital stay, an expected average of 2 hours
|
Investigate the adverse events according to the Adverse event reporting tool of the world SIVA International Sedation Task Force during upper gastrointestinal endoscopy with and without sedation.
|
Patients will be followed for the duration of hospital stay, an expected average of 2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Diansan Su, Doctor, Renji Hospital, School of Medicine, Shanghai Jiaotong University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AEDUGESSH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
NCT06342427CompletedGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion
-
NCT03997162Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric Cancer AJCC v8 | Pathologic Stage I Gastric Cancer AJCC v8 | Pathologic Stage IA Gastric Cancer AJCC v8
-
NCT04523818Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic Stage IIA Gastric Cancer AJCC v8 | Pathologic Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage III Gastric Cancer AJCC v8
-
NCT01939275CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer | Stage IIA Gastric Cancer
-
NCT00062374CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric Cancer
-
NCT06702683RecruitingGastric Carcinoma | Gastric Neoplasm | Gastric Cancer Adenocarcinoma Metastatic | Gastric (cardia, Body) Cancer
-
NCT06755554RecruitingGastric Cancer | Gastrectomy for Gastric Cancer | Gastric Cancer Stage III | Gastric Cancer Stage II
-
NCT03257163Active, not recruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7
-
NCT02730546CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7
-
NCT07621484Not yet recruitingGastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastric Cancer